JNJ targets COVID-19 late-stage trial results by January

Cropped hand wearing a nitrile glove holding a Covid-19 vaccine vial and a syringe
Cropped hand wearing a nitrile glove holding a Covid-19 vaccine vial and a syringe

U.S. company Johnson & Johnson could obtain late-stage trial results of a COVID-19 vaccine it is developing earlier than expected, its chief scientist, Paul Stoffels said according to a Reuters report.

Johnson & Johnson said last month that it was hoping to have all the data needed to seek U.S authorization by February.

J&J’s candidate is a single-dose vaccine, whereas the vaccines from Moderna and Pfizer and another under development by AstraZeneca all require two shots several weeks apart.